NEDD9‐deficient p210‐BCR/ABL transgenic mice show an increased number of granulocytes in peripheral blood, a hyperplasia of myeloid and megakaryocytic cells in the bone marrow and a diffuse myeloid infiltration in the spleen, lung and liver, leading to earlier progression and shorter mouse survival, which support NEDD9 capacity to block chronic myeloid leukaemia (CML) progression.23 Here, NEDD9 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.